annual meeting program - American Society of Clinical Oncology

Monday, June 7, 2010
Brd. 3H A phase I safety and tolerability study of vorinostat (V) in combination with
sorafenib (S) in patients with advanced solid tumors, with exploration of two
tumor-type specific expanded cohorts at the recommended phase II dose
(renal and non-small cell lung carcinoma). (Abstract #2562)
A. Dasari, L. Gore, W. A. Messersmith, S. Diab, A. Jimeno, C. D. Weekes,
K. D. Lewis, H. A. Drabkin, T. W. Flaig, D. R. Camidge
Brd. 4A A phase I study of bortezomib (BTZ) and temozolomide (TMZ) in patients with
advanced solid tumors. (Abstract #2563)
J. Portnow, S. Koehler, M. C. Cristea, W. A. Chow, V. M. Chung, D. Lim,
R. Morgan, S. Shibata, P. H. Frankel, T. W. Synold
Brd. 4B Nano-immunoassay profiling of ERK and MEK isoforms in fine-needle
aspirates of solid tumors. (Abstract #2564)
A. C. Fan, J. Dermody, C. Kong, N. Zhang, A. D. Colevas, D. W. Felsher
Brd. 4C Effect of a novel II-key hybrid HER2/neu peptide (AE37) vaccine with GM-CSF
as compared to GM-CSF alone on levels of regulatory T-cell (Treg)
populations. (Abstract #2565)
G. T. Clifton, K. S. Clive, R. Patil, J. P. Holmes, L. C. Benavides, J. D. Gates,
J. Tyler, E. A. Mittendorf, S. Ponniah, G. E. Peoples
Brd. 4D Pharmacology of high-dose methotrexate in patients with primary CNS
lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG
#20 trial. (Abstract #2566)
A. J. Ferreri, M. Joerger, A. D. Huitema, S. Krähenbühl, J. H. Schellens, T. Cerny,
M. Reni, E. Zucca, F. Cavalli
Brd. 4E Effect of TGF-�1 expressed on tumor-derived exosomes on survival and
function of regulatory T cells. (Abstract #2567)
H. Onishi, J. Wada, H. Suzuki, A. Yamasaki, S. Nagai, T. Morisaki, M. Katano
Brd. 4F Factors of interindividual hematopoietic toxicity of carboplatin. (Abstract
#2568)
E. Chatelut, A. Schmitt, N. Penel, M. Campone, R. Largillier, P. Soulié, M. Fabbro,
N. Houede, J. Medioni, P. Bougnoux, Groupe de Pharmacologie Clinique en
Oncologie
Brd. 4G Effect of prophylactic administration of recombinant human thrombopoietin
on chemotherapy-induced severe thrombocytopenia in patients with
advanced non-small cell lung cancer: A prospective self-control clinic study.
(Abstract #2569)
S. Lu, Y. Xu
Brd. 4H A phase I study of ARRY-520 in solid tumors. (Abstract #2570)
P. H. Goncalves, E. A. Sausville, M. J. Edelman, N. B. Pandya, M. M. Houlehan,
B. B. Freeman, H. M. Simmons, J. S. Stallings, A. M. Ptaszynski, P. LoRusso
Brd. 5A A phase I and pharmacokinetic single agent study of pazopanib (P) in
patients (Pts) with advanced malignancies and varying degrees of liver
dysfunction (LD). (Abstract #2571)
S. Shibata, J. Longmate, V. M. Chung, H. Lenz, S. Kummar, J. Sarantopoulos,
M. L. Harrison, T. W. Synold, S. P. Ivy, E. M. Newman
Brd. 5B Phase I, pharmacokinetic study of temsirolimus in combination with
nelfinavir in patients with solid tumors. (Abstract #2572)
W. Kromdijk, A. D. Huitema, M. E. Kemper, J. H. Schellens, D. Richel, H. Klumpen
Brd. 5C Phase I safety and pharmacology study of the EpCAM/CD3-bispecific BiTE
antibody MT110 in patients with metastatic colorectal, gastric, or lung
cancer. (Abstract #2573^)
W. M. Fiedler, B. Ritter, R. Seggewiss, C. Bokemeyer, P. Fettes, M. Klinger,
E. Vieser, D. Ruettinger, S. Kaubitzsch, M. Wolf
Brd. 5D Clinical outcome of first-line melanoma patients who continue tremelimumab
in spite of early disease progression. (Abstract #2574)
D. I. Healey, P. S. Carlson, B. Huang, M. A. Marshall
303
MONDAY